WO2005009407A3 - Oral pharmaceutical formulations of olanzapine - Google Patents

Oral pharmaceutical formulations of olanzapine Download PDF

Info

Publication number
WO2005009407A3
WO2005009407A3 PCT/IB2004/051335 IB2004051335W WO2005009407A3 WO 2005009407 A3 WO2005009407 A3 WO 2005009407A3 IB 2004051335 W IB2004051335 W IB 2004051335W WO 2005009407 A3 WO2005009407 A3 WO 2005009407A3
Authority
WO
WIPO (PCT)
Prior art keywords
olanzapine
pharmaceutical formulations
oral pharmaceutical
powder
coating
Prior art date
Application number
PCT/IB2004/051335
Other languages
French (fr)
Other versions
WO2005009407A2 (en
Inventor
Vivek Mahendrakumar Dubey
Abhijit Mukund Deshmukh
Sanjeev Kumar Sethi
Rajiv Malik
Original Assignee
Ranbaxy Lab Ltd
Vivek Mahendrakumar Dubey
Abhijit Mukund Deshmukh
Sanjeev Kumar Sethi
Rajiv Malik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Vivek Mahendrakumar Dubey, Abhijit Mukund Deshmukh, Sanjeev Kumar Sethi, Rajiv Malik filed Critical Ranbaxy Lab Ltd
Publication of WO2005009407A2 publication Critical patent/WO2005009407A2/en
Publication of WO2005009407A3 publication Critical patent/WO2005009407A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Abstract

The present invention relates to olanzapine formulations stable to discoloration. The pharmaceutical formulations include olanzapine particles or powder, and a coating on the olanzapine particles or powder. The coating includes lactose and/or mannitol and optionally one or more pharmaceutically acceptable excipients.
PCT/IB2004/051335 2003-07-29 2004-07-29 Oral pharmaceutical formulations of olanzapine WO2005009407A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN939/DEL/2003 2003-07-29
IN939DE2003 2003-07-29

Publications (2)

Publication Number Publication Date
WO2005009407A2 WO2005009407A2 (en) 2005-02-03
WO2005009407A3 true WO2005009407A3 (en) 2006-03-02

Family

ID=34090480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/051335 WO2005009407A2 (en) 2003-07-29 2004-07-29 Oral pharmaceutical formulations of olanzapine

Country Status (1)

Country Link
WO (1) WO2005009407A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GEP20115245B (en) * 2005-12-22 2011-06-27 Takeda Pharmaceutical Solid preparation
ES2279715B1 (en) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. ORAL FORMULATION OF OLANZAPINE.
CL2007002807A1 (en) * 2006-09-29 2008-04-11 Synthon Bv PHARMACEUTICAL COMPOSITION IN SOLID STATE THAT INCLUDES OLANZAPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND LACTOSE ANHYDRA; ORAL PHARMACEUTICAL TABLET; PROCEDURE FOR PREPARATION OF SUCH TABLET, USEFUL IN THE TREATMENT OF SKI
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
WO2010100658A2 (en) * 2009-03-05 2010-09-10 Genepharm India Private Limited Stable olanzapine tablets and the process for its preparation
CN103006600B (en) * 2013-01-04 2014-11-19 青岛大学 Benzenesulfonate amlodipine tablet and preparation method thereof
EP3038465B1 (en) 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
CN104721163A (en) * 2015-04-09 2015-06-24 海南华益泰康药业有限公司 Sustained release tablet containing lamotrigine and preparing method thereof
CN108261399A (en) * 2016-12-30 2018-07-10 江苏豪森药业集团有限公司 Olanzapine oral disnitegration tablet and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733367A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Oral olanzapine formulation
EP0830858A1 (en) * 1996-09-24 1998-03-25 Eli Lilly And Company Formulation comprising coated olanzapine particles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733367A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Oral olanzapine formulation
US5919485A (en) * 1995-03-24 1999-07-06 Eli Lilly And Company Oral 2-methyl-thieno-benzodiazepine formulation
EP0830858A1 (en) * 1996-09-24 1998-03-25 Eli Lilly And Company Formulation comprising coated olanzapine particles

Also Published As

Publication number Publication date
WO2005009407A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
MY148466A (en) Granule formulation
AU2002333644A1 (en) Dry powder medicament formulations
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
CA2427815A1 (en) Controlled release hydrocodone formulations
MXPA03007215A (en) Pharmaceutical formulations.
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
WO2004032866A3 (en) Therapeutic formulations
WO2005009407A3 (en) Oral pharmaceutical formulations of olanzapine
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
WO2005039481A3 (en) Oral drug delivery system
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
AU2003304236A1 (en) Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
WO2005030142A3 (en) Rifalazil formulations
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
IL162510A0 (en) Pharmaceutical suspension for oral administration
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 559/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase